In a subset of these patients, the sporadic nature of the disease could potentially be explained by the early death of one or both parents (3/22), adoption (1/22), or a lack of sufficient information (8/22); however, in 10 patients the clinical records suggested a true sporadic nature of the disease. The GGGGCC repeat was found in 18.3% of all patients with FTLD-TDP pathology from the MCF brain bank, and explained 22.5% of familial cases in this series. It should be noted however,

that this is a dementia-focused series with an underrepresentation of ALS. The frequency in our clinical FTD patient series was 3.0% of sporadic cases and 11.7% of familial patients. In our clinical ALS series, 4.1% of the sporadic and 23.5% of patients with a positive family history carried repeat expansions. this website Importantly, a direct comparison of the frequency of repeat expansions in C9ORF72 with mutations in SOD1, TARDBP, and FUS revealed GGGGCC expansions to be the most common genetic

cause of sporadic and familial ALS in our clinical series ( Table 1). In clinical FTD, GGGGCC repeat expansions were found to be more common than either GRN or microtubule associated protein tau (MAPT) mutations in familial cases, and of equal frequency to GRN mutations in sporadic FTD. Clinical data was obtained for the 26 unrelated expanded repeat carriers from the clinical FTD series and the 16 unrelated carriers from the ALS series. The median age of onset was comparable in the two series (FTD: Navitoclax price 56.2 years, range 34–72 years; ALS: 54.5 years, range 41–72 years), with a slightly shorter mean disease duration in the ALS patients (FTD: 5.1 ± 3.1 years, range 1–12 years, n = 18; ALS: 3.6 ± 1.6 years, range

1–6 years, n = 7). The FTD phenotype was predominantly behavioral variant FTD (bvFTD) (25/26). Importantly, seven patients from the FTD series (26.9%) had concomitant ALS and eight patients (30.7%) had relatives affected with ALS. In comparison, the frequency of a family history of ALS in the remainder of our FTD population (those without repeat expansions) aminophylline was only 5/348 (1.4%). In the ALS series, all mutation carriers presented with classical ALS with the exception of one patient diagnosed with progressive muscular atrophy without upper motor neuron signs. Three patients (18.8%) were diagnosed with a combined ALS/FTD phenotype. In the ALS patients with expanded repeats, 11/16 (68.8%) reported relatives with FTD or dementia, compared to only 61/213 (28.6%) of ALS patients without repeat expansions. Finally, autopsy was subsequently performed on 11 FTD and three ALS expanded repeat carriers from the clinical series, and in all cases, TDP-43 based pathology was confirmed.